Figure 2.

PSA Response by dose group—High Dose vs. Moderate Dose. Although the median 5 year result is very low in both groups (0.1 ng/mL moderate dose, 0.034 ng/mL high dose), there are noteworthy differences. At every comparative time point except 36 months, where they are transiently equal, the median PSA is lower in the high dose group. At every comparative time point except 30 months, the 25th-75th percentile range is lower and with a smaller spread in the high dose group. At 4 years, the difference reaches statistical significance, favoring a lower median PSA nadir in the high dose group, remaining of borderline significance at 5 years. These differences are seen in spite of adverse patient selection in the high dose group, which contains a significantly greater proportion of Gleason score 7 patients and a significantly greater proportion of younger patients, relative to the moderate dose group.